Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

A federal study revealed that the pharmaceutical company Wyeth paid ghostwriters to write articles for medical journals that were favorable to the drug company’s hormone replacement therapy (HRT) Prempro, even after the drug was found to raise a woman’s risk for breast cancer, according to the New York Times.

Read the rest of this entry »

Wyeth, the pharmaceutical company that makes hormone replacement therapies Prempro and Premarin, announced today that it is ending its research in its signature areas of contraceptives and menopause treatments to focus on other female problems such as ovarian and breast cancers, according to the Associated Press/Washington Post.

Read the rest of this entry »

Drug maker Wyeth has developed and is actively testing a new drug to treat menopause. The drug, named Aprela, has shown favorable results in the initial studies. Current evidence gathered in the study suggests that the drug may pose fewer risks and milder side effects than Prempro and Premarin, Wyeth’s other menopause drugs.

Read the rest of this entry »

Wyeth must pay $134.1 million, including $99 million in punitive damages, over its mishandling of menopause drugs that helped cause three Nevada women’s cancers, a jury ruled.

Read the rest of this entry »